Historical Valuation
Biogen Inc (BIIB) is now in the Fair zone, suggesting that its current forward PE ratio of 13.80 is considered Fairly compared with the five-year average of 14.15. The fair price of Biogen Inc (BIIB) is between 153.55 to 226.74 according to relative valuation methord.
Relative Value
Fair Zone
153.55-226.74
Current Price：185.63
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Biogen Inc (BIIB) has a current Price-to-Book (P/B) ratio of 1.43. Compared to its 3-year average P/B ratio of 1.98 , the current P/B ratio is approximately -27.48% higher. Relative to its 5-year average P/B ratio of 2.57, the current P/B ratio is about -44.35% higher. Biogen Inc (BIIB) has a Forward Free Cash Flow (FCF) yield of approximately 8.83%. Compared to its 3-year average FCF yield of 6.55%, the current FCF yield is approximately 34.95% lower. Relative to its 5-year average FCF yield of 6.89% , the current FCF yield is about 28.27% lower.
P/B
Median3y
1.98
Median5y
2.57
FCF Yield
Median3y
6.55
Median5y
6.89
Competitors Valuation Multiple
AI Analysis for BIIB
The average P/S ratio for BIIB competitors is 4.52, providing a benchmark for relative valuation. Biogen Inc Corp (BIIB.O) exhibits a P/S ratio of 2.83, which is -37.46% above the industry average. Given its robust revenue growth of 2.79%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BIIB
1Y
3Y
5Y
Market capitalization of BIIB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BIIB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BIIB currently overvalued or undervalued?
Biogen Inc (BIIB) is now in the Fair zone, suggesting that its current forward PE ratio of 13.80 is considered Fairly compared with the five-year average of 14.15. The fair price of Biogen Inc (BIIB) is between 153.55 to 226.74 according to relative valuation methord.
What is Biogen Inc (BIIB) fair value?
BIIB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Biogen Inc (BIIB) is between 153.55 to 226.74 according to relative valuation methord.
How does BIIB's valuation metrics compare to the industry average?
The average P/S ratio for BIIB's competitors is 4.52, providing a benchmark for relative valuation. Biogen Inc Corp (BIIB) exhibits a P/S ratio of 2.83, which is -37.46% above the industry average. Given its robust revenue growth of 2.79%, this premium appears unsustainable.
What is the current P/B ratio for Biogen Inc (BIIB) as of Jan 13 2026?
As of Jan 13 2026, Biogen Inc (BIIB) has a P/B ratio of 1.43. This indicates that the market values BIIB at 1.43 times its book value.
What is the current FCF Yield for Biogen Inc (BIIB) as of Jan 13 2026?
As of Jan 13 2026, Biogen Inc (BIIB) has a FCF Yield of 8.83%. This means that for every dollar of Biogen Inc’s market capitalization, the company generates 8.83 cents in free cash flow.
What is the current Forward P/E ratio for Biogen Inc (BIIB) as of Jan 13 2026?
As of Jan 13 2026, Biogen Inc (BIIB) has a Forward P/E ratio of 13.80. This means the market is willing to pay $13.80 for every dollar of Biogen Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Biogen Inc (BIIB) as of Jan 13 2026?
As of Jan 13 2026, Biogen Inc (BIIB) has a Forward P/S ratio of 2.83. This means the market is valuing BIIB at $2.83 for every dollar of expected revenue over the next 12 months.